Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1970 1
1974 1
1977 1
1978 3
1980 2
1983 1
1984 1
1986 1
1987 2
1988 1
1989 3
1990 2
1991 4
1992 3
1993 4
1995 2
1996 3
1997 2
1998 1
1999 3
2000 3
2001 9
2002 5
2003 4
2004 2
2005 3
2006 7
2007 3
2008 1
2009 7
2010 7
2011 8
2012 11
2013 8
2014 18
2015 12
2016 7
2017 10
2018 8
2019 15
2020 18
2021 17
2022 16
2023 26
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. Among authors: zielinski rr. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: zielinski rr. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Dempke WCM, et al. Among authors: zielinski r. Eur J Cancer. 2023 May;185:94-104. doi: 10.1016/j.ejca.2023.02.019. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36966697 Free article. Review.
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents.
Pajak B, Siwiak E, Sołtyka M, Priebe A, Zieliński R, Fokt I, Ziemniak M, Jaśkiewicz A, Borowski R, Domoradzki T, Priebe W. Pajak B, et al. Among authors: zielinski r. Int J Mol Sci. 2019 Dec 29;21(1):234. doi: 10.3390/ijms21010234. Int J Mol Sci. 2019. PMID: 31905745 Free PMC article. Review.
Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer.
Becker LM, O'Connell JT, Vo AP, Cain MP, Tampe D, Bizarro L, Sugimoto H, McGow AK, Asara JM, Lovisa S, McAndrews KM, Zielinski R, Lorenzi PL, Zeisberg M, Raza S, LeBleu VS, Kalluri R. Becker LM, et al. Among authors: zielinski r. Cell Rep. 2020 Jun 2;31(9):107701. doi: 10.1016/j.celrep.2020.107701. Cell Rep. 2020. PMID: 32492417 Free PMC article.
N-Heterocyclic Olefins on a Silicon Surface.
Das M, Hogan C, Zielinski R, Kubicki M, Koy M, Kosbab C, Brozzesi S, Das A, Nehring MT, Balfanz V, Brühne J, Dähne M, Franz M, Esser N, Glorius F. Das M, et al. Among authors: zielinski r. Angew Chem Int Ed Engl. 2023 Dec 11;62(50):e202314663. doi: 10.1002/anie.202314663. Epub 2023 Nov 9. Angew Chem Int Ed Engl. 2023. PMID: 37849449
Zirconium Surface Treatment via Chemical Etching.
Gołasz P, Kołkowska A, Zieliński R, Simka W. Gołasz P, et al. Among authors: zielinski r. Materials (Basel). 2023 Nov 28;16(23):7404. doi: 10.3390/ma16237404. Materials (Basel). 2023. PMID: 38068148 Free PMC article.
256 results